VEGF-A、C、D在恩度不同给药方式治疗恶性浆膜腔积液中疗效预测的临床意义  

The predictive value of VEGF-A,C,D for the clinical efficacy of different approaches of endostar in treatment of malignant dropsy of serous cavity

作　　者：王颖 吕雅蕾[2] 高春晖 洪丹[5] 杨琳[5] 任冠颖 宋新梅 贾琳 WANG Ying;LV Yalei;GAO Chunhui(Department of Oncology,The Second Hospital of Baoding City,Hebei,Baoding 071000,China)

机构地区：[1]河北省保定市第二医院肿瘤内科,071000 [2]河北医科大学第四医院肿瘤内科 [3]河北省保定市第一中心医院乳腺外科 [4]河北省保定市第一中心医院肿瘤内科 [5]河北大学附属医院肿瘤内科

出　　处：《河北医药》2019年第17期2649-2652,共4页Hebei Medical Journal

摘　　要：目的评价VEGF-A、C、D在不同方式恩度治疗恶性浆膜腔积液中的疗效预测价值。方法应用酶联免疫吸附实验(ELISA)方法,检测20对恶性浆膜腔积液患者积液上清VEGF-A、C、D蛋白含量。结果局部恩度组,局部恩度+顺铂组及局部恩度+全身治疗组,在客观有效率RR(CR+PR),临床获益率DCR(CR+PR+SD)及局部进展PD差异无统计学意义(P>0.05)。积液上清VEGF-A差值比[(d 0-d 7)/d 0]在RR,SD,PD组差异无统计学意义(P=0.085)。积液上清VEGF-A、C、D差值比[(d 0-d 7)/d 0]在3治疗组差异无统计学意义(P>0.05)。结论积液上清VEGF-A有预测局部恩度治疗疗效的潜力,尚不能依据积液上清VEGF-A、C、D决策靶向或化疗的优先用药及组合方式。Objective To evaluate the predictive value of VEGF-A,C,D for the clinical efficacy of different approaches of endostar in treatment of malignant dropsy of serous cavity.Methods ELISA was used to detect the protein contents of VEGF-A,C,D in 20 pairs of patients with malignant dropsy of serous cavity who were treated by intracavitary.Results There were no significant differences in the objective response rate(RR:CR+PR),clinical benefit rate(DCR:CR+PR+NC)and local progression(PD)among endostar monotherapy group,endostar plus cisplatin group and endostar monotherapy combined with systemic anti-tumor therapy group(P>0.05)There was no significant difference in the difference ratio of the supernatant VEGF-A[(d 0-d 7)/d 0]among RR group,SD group,PD group(P>0.05).There was no significant difference in the difference ratio of the supernatant VEGF-A,C,D[(d 0-d 7)/d 0]among the three treatment groups(P>0.05).Conclusion Supernatant fluid VEGF-A has the potential significance to predict the therapeutic effects of endostar,however,it is not decided yet to guide the priority of targeting or chemotherapy as well as the combination treatment according to supernatant fluid VEGF-A,C,D.

关 键 词：恶性浆膜腔积液 VEGF-A、C、D 恩度 治疗结果 

分 类 号：R561.3[医药卫生—呼吸系统]